Answers are grounded in this paper and cite their sources.
The US Food and Drug Administration (FDA) is requiring new safety changes to the labels of all products containing estrogen alone or combined with progestin for use by postmenopausal women, warning that the drugs may slightly increase the risk of heart attack, stroke, breast cancer, and blood clots.
No takes yet. Share an insight, caveat, or question.
Joan Stephenson (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: